|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GOLPH3 |
Gene summary for GOLPH3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GOLPH3 | Gene ID | 64083 |
| Gene name | golgi phosphoprotein 3 | |
| Gene Alias | GOPP1 | |
| Cytomap | 5p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q9H4A6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64083 | GOLPH3 | CCI_1 | Human | Cervix | CC | 4.95e-04 | 6.57e-01 | 0.528 |
| 64083 | GOLPH3 | CCI_3 | Human | Cervix | CC | 1.07e-06 | 6.50e-01 | 0.516 |
| 64083 | GOLPH3 | sample3 | Human | Cervix | CC | 1.15e-07 | 2.51e-01 | 0.1387 |
| 64083 | GOLPH3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.71e-14 | -5.18e-01 | 0.0155 |
| 64083 | GOLPH3 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.81e-03 | -2.31e-01 | -0.1464 |
| 64083 | GOLPH3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.72e-07 | -3.28e-01 | 0.0674 |
| 64083 | GOLPH3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.28e-13 | -4.22e-01 | 0.3005 |
| 64083 | GOLPH3 | F007 | Human | Colorectum | FAP | 4.72e-03 | -3.21e-01 | 0.1176 |
| 64083 | GOLPH3 | A002-C-010 | Human | Colorectum | FAP | 1.15e-03 | -1.55e-01 | 0.242 |
| 64083 | GOLPH3 | A015-C-203 | Human | Colorectum | FAP | 9.00e-29 | -3.47e-01 | -0.1294 |
| 64083 | GOLPH3 | A015-C-204 | Human | Colorectum | FAP | 3.74e-05 | -2.24e-01 | -0.0228 |
| 64083 | GOLPH3 | A014-C-040 | Human | Colorectum | FAP | 1.10e-05 | -4.38e-01 | -0.1184 |
| 64083 | GOLPH3 | A002-C-201 | Human | Colorectum | FAP | 1.52e-13 | -2.97e-01 | 0.0324 |
| 64083 | GOLPH3 | A002-C-203 | Human | Colorectum | FAP | 1.93e-07 | -1.98e-01 | 0.2786 |
| 64083 | GOLPH3 | A001-C-119 | Human | Colorectum | FAP | 3.06e-08 | -2.82e-01 | -0.1557 |
| 64083 | GOLPH3 | A001-C-108 | Human | Colorectum | FAP | 7.58e-18 | -3.17e-01 | -0.0272 |
| 64083 | GOLPH3 | A002-C-205 | Human | Colorectum | FAP | 1.25e-19 | -2.78e-01 | -0.1236 |
| 64083 | GOLPH3 | A014-C-108 | Human | Colorectum | FAP | 1.38e-02 | -3.39e-01 | -0.124 |
| 64083 | GOLPH3 | A001-C-104 | Human | Colorectum | FAP | 1.06e-08 | -2.88e-01 | 0.0184 |
| 64083 | GOLPH3 | A015-C-006 | Human | Colorectum | FAP | 1.90e-14 | -4.55e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512225 | Colorectum | CRC | positive regulation of protein transport | 61/2078 | 303/18723 | 2.73e-06 | 1.27e-04 | 61 |
| GO:00068933 | Colorectum | CRC | Golgi to plasma membrane transport | 20/2078 | 60/18723 | 3.80e-06 | 1.61e-04 | 20 |
| GO:00481935 | Colorectum | CRC | Golgi vesicle transport | 59/2078 | 296/18723 | 5.47e-06 | 2.17e-04 | 59 |
| GO:00300323 | Colorectum | CRC | lamellipodium assembly | 22/2078 | 72/18723 | 6.40e-06 | 2.47e-04 | 22 |
| GO:19049515 | Colorectum | CRC | positive regulation of establishment of protein localization | 62/2078 | 319/18723 | 7.44e-06 | 2.72e-04 | 62 |
| GO:00069005 | Colorectum | CRC | vesicle budding from membrane | 19/2078 | 61/18723 | 1.99e-05 | 5.90e-04 | 19 |
| GO:00160504 | Colorectum | CRC | vesicle organization | 57/2078 | 300/18723 | 3.36e-05 | 8.57e-04 | 57 |
| GO:00901505 | Colorectum | CRC | establishment of protein localization to membrane | 51/2078 | 260/18723 | 3.59e-05 | 9.05e-04 | 51 |
| GO:00430014 | Colorectum | CRC | Golgi to plasma membrane protein transport | 14/2078 | 40/18723 | 5.81e-05 | 1.31e-03 | 14 |
| GO:00507084 | Colorectum | CRC | regulation of protein secretion | 49/2078 | 268/18723 | 3.00e-04 | 4.75e-03 | 49 |
| GO:00340672 | Colorectum | CRC | protein localization to Golgi apparatus | 10/2078 | 29/18723 | 7.59e-04 | 9.71e-03 | 10 |
| GO:00093064 | Colorectum | CRC | protein secretion | 59/2078 | 359/18723 | 1.32e-03 | 1.48e-02 | 59 |
| GO:00901623 | Colorectum | CRC | establishment of epithelial cell polarity | 10/2078 | 31/18723 | 1.37e-03 | 1.50e-02 | 10 |
| GO:00355924 | Colorectum | CRC | establishment of protein localization to extracellular region | 59/2078 | 360/18723 | 1.41e-03 | 1.54e-02 | 59 |
| GO:00716924 | Colorectum | CRC | protein localization to extracellular region | 59/2078 | 368/18723 | 2.37e-03 | 2.27e-02 | 59 |
| GO:19035323 | Colorectum | CRC | positive regulation of secretion by cell | 47/2078 | 282/18723 | 2.91e-03 | 2.64e-02 | 47 |
| GO:00973054 | Colorectum | CRC | response to alcohol | 43/2078 | 253/18723 | 2.96e-03 | 2.66e-02 | 43 |
| GO:00510474 | Colorectum | CRC | positive regulation of secretion | 50/2078 | 310/18723 | 4.31e-03 | 3.47e-02 | 50 |
| GO:00516514 | Colorectum | CRC | maintenance of location in cell | 36/2078 | 214/18723 | 7.25e-03 | 4.98e-02 | 36 |
| GO:004819317 | Esophagus | HGIN | Golgi vesicle transport | 83/2587 | 296/18723 | 8.59e-11 | 8.89e-09 | 83 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GOLPH3 | SNV | Missense_Mutation | c.255N>G | p.Ile85Met | p.I85M | Q9H4A6 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AR-A1AS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| GOLPH3 | SNV | Missense_Mutation | c.769N>G | p.Leu257Val | p.L257V | Q9H4A6 | protein_coding | tolerated(0.29) | benign(0.033) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| GOLPH3 | insertion | Frame_Shift_Ins | novel | c.562_563insAACCAGAAGT | p.Thr188LysfsTer14 | p.T188Kfs*14 | Q9H4A6 | protein_coding | TCGA-BH-A0H0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| GOLPH3 | insertion | Frame_Shift_Ins | novel | c.573_574insTTCTC | p.Gln192PhefsTer10 | p.Q192Ffs*10 | Q9H4A6 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| GOLPH3 | SNV | Missense_Mutation | rs192633198 | c.704G>A | p.Arg235His | p.R235H | Q9H4A6 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| GOLPH3 | SNV | Missense_Mutation | c.311N>C | p.Gln104Pro | p.Q104P | Q9H4A6 | protein_coding | tolerated(0.23) | benign(0.006) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GOLPH3 | SNV | Missense_Mutation | c.394N>G | p.Leu132Val | p.L132V | Q9H4A6 | protein_coding | deleterious(0.02) | benign(0.193) | TCGA-DM-A28H-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
| GOLPH3 | SNV | Missense_Mutation | rs773095936 | c.520N>T | p.Arg174Trp | p.R174W | Q9H4A6 | protein_coding | deleterious(0.02) | benign(0.214) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GOLPH3 | SNV | Missense_Mutation | c.527N>A | p.Arg176Gln | p.R176Q | Q9H4A6 | protein_coding | deleterious(0) | benign(0.332) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
| GOLPH3 | SNV | Missense_Mutation | novel | c.502T>C | p.Tyr168His | p.Y168H | Q9H4A6 | protein_coding | tolerated(0.06) | benign(0.251) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |